Advertisement

Topics

Affigen Announces $17 Million Series A Led by Black Beret Life Sciences

09:00 EST 21 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Funding for Development of Cancer Immunotherapies Targeting Cell Lineage-Specific Tumor Proteins Affigen, a biotechnology company that develops therapeutics targeting cell lineage-specific tumor proteins, today announced the...

Other Sources for this Article

Affigen
Jonathan Feldmann, +1 314-254-5081
Chief Operating Officer
pr@affigen.com

NEXT ARTICLE

More From BioPortfolio on "Affigen Announces $17 Million Series A Led by Black Beret Life Sciences"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...